Wuxi Biologics (Cayman) Inc.

As of December 31, 2025, WuXi Biologics (Cayman) Inc. Units Thailand Depositery Receipt Repr 0.01 Sh carries a market capitalization of 530.53B, placing it among publicly traded companies globally. Its enterprise value stands at 499.83B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

WuXi Biologics (Cayman) Inc. Units Thailand Depositery Receipt Repr 0.01 Sh's next confirmed earnings release is scheduled for March 23, 2027.

As of December 31, 2025, WuXi Biologics (Cayman) Inc. Units Thailand Depositery Receipt Repr 0.01 Sh has 278.84B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, WuXi Biologics (Cayman) Inc. Units Thailand Depositery Receipt Repr 0.01 Sh maintains a current ratio of 3.39, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

These figures are as of the close on October 22, 2026.

As of December 31, 2025, WuXi Biologics (Cayman) Inc. Units Thailand Depositery Receipt Repr 0.01 Sh holds 70.63B in cash and equivalents against 13.94B in total debt, resulting in a net debt position of -36.68B. Total book value stands at 212.13B, with working capital of 89.02B providing operational flexibility.